EXECUTIVE SEPARATION AND RELEASE AGREEMENTExecutive Separation and Release Agreement • March 29th, 2022 • Humacyte, Inc. • Biological products, (no disgnostic substances) • North Carolina
This Executive Separation and Release Agreement (“Agreement”) is entered into by and between Humacyte, Inc. (“Humacyte”) and Jeffrey Lawson, M.D., Ph.D. (“Executive”), effective as of the date signed by Executive (the “Effective Date”). Humacyte and Executive are collectively referred to as the “Parties.”
SIXTH AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • March 29th, 2022 • Humacyte, Inc. • Biological products, (no disgnostic substances) • North Carolina
This Sixth Amendment (this “Sixth Amendment”), effective as of January 10, 2022 (“EFFECTIVE DATE”), amends the Exclusive Patent License Agreement, effective March 14, 2006, as amended by the First Amendment to Exclusive Patent License Agreement, effective as of February 25, 2011, the Second Amendment to Exclusive Patent License Agreement, effective as of April 24, 2014, the Third Amendment to Exclusive patent License Agreement, dates as of June 26, 2015, the Fourth Amendment to Exclusive Patent License Agreement, effective as of January 2, 2018, and the Fifth Amendment to Patent Exclusive Patent License Agreement, effective as of December 31, 2019 (as so amended, the “Agreement”), between Duke University, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”) having its principal office in Durham, North Carolina, and Humacyte, Inc., a corporation organized under the laws of Delaware (“COMPANY”) with its corporate headquarters and principal
